Compare LPA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | MGNX |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.0M | 220.6M |
| IPO Year | 2023 | 2013 |
| Metric | LPA | MGNX |
|---|---|---|
| Price | $2.84 | $4.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 19.1K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.04 | $1.19 |
| 52 Week High | $8.34 | $4.64 |
| Indicator | LPA | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 59.77 |
| Support Level | $2.56 | $1.48 |
| Resistance Level | $3.33 | N/A |
| Average True Range (ATR) | 0.25 | 0.32 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 14.73 | 73.10 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.